Coya Therapeutics (NASDAQ:COYA – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.32) per share for the quarter.
Coya Therapeutics Stock Up 0.2 %
Shares of COYA opened at $6.49 on Monday. Coya Therapeutics has a twelve month low of $4.75 and a twelve month high of $10.69. The stock has a market capitalization of $108.43 million, a P/E ratio of -9.98 and a beta of 0.31. The firm has a fifty day simple moving average of $6.28 and a two-hundred day simple moving average of $6.47.
Analyst Ratings Changes
A number of analysts have recently issued reports on the stock. Chardan Capital reaffirmed a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a report on Thursday, February 6th. D. Boral Capital reissued a “buy” rating and issued a $15.00 price objective on shares of Coya Therapeutics in a report on Monday, March 10th.
Coya Therapeutics Company Profile
Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Further Reading
- Five stocks we like better than Coya Therapeutics
- How to Short a Stock in 5 Easy Steps
- How to Build the Ultimate Everything ETF Portfolio
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
